PURPOSE: We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma. MATERIALS AND METHODS: Of the 25 patients included in a prospective multicenter phase II trial 23 were evaluable for efficacy and toxicity studies after pathological review. RESULTS: A median of 3 cycles per patient (range 1 to 8) was administered. No objective response was observed. Median time to progression was 2.2 months and median overall survival was 3.9 months. A single patient died of toxicity. CONCLUSIONS: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma.
PURPOSE: We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma. MATERIALS AND METHODS: Of the 25 patients included in a prospective multicenter phase II trial 23 were evaluable for efficacy and toxicity studies after pathological review. RESULTS: A median of 3 cycles per patient (range 1 to 8) was administered. No objective response was observed. Median time to progression was 2.2 months and median overall survival was 3.9 months. A single patient died of toxicity. CONCLUSIONS: The results do not support the standard use of doxorubicin/ifosfamide chemotherapy in patients with metastatic sarcomatoid renal cell carcinoma.
Authors: Ana M Molina; Satish K Tickoo; Nicole Ishill; Michael J Trinos; Lawrence H Schwartz; Sujata Patil; Darren R Feldman; Victor E Reuter; Paul Russo; Robert J Motzer Journal: Am J Clin Oncol Date: 2011-10 Impact factor: 2.339
Authors: Cedric Lebacle; Aydin Pooli; Thomas Bessede; Jacques Irani; Allan J Pantuck; Alexandra Drakaki Journal: World J Urol Date: 2018-06-01 Impact factor: 4.226
Authors: Simon Chowdhury; Marc R Matrana; Christopher Tsang; Bradley Atkinson; Toni K Choueiri; Nizar M Tannir Journal: Hematol Oncol Clin North Am Date: 2011-08 Impact factor: 3.722
Authors: Sumanta K Pal; Jeremy O Jones; Courtney Carmichael; Junmi Saikia; Joanne Hsu; Xueli Liu; Robert A Figlin; Przemyslaw Twardowski; Clayton Lau Journal: Urol Oncol Date: 2012-05-17 Impact factor: 3.498
Authors: Daniel P Nguyen; Antoni Vilaseca; Emily A Vertosick; Renato B Corradi; Karim A Touijer; Nicole E Benfante; Daniel D Sjoberg; Paul Russo Journal: World J Urol Date: 2015-07-28 Impact factor: 4.226